Boston Scientific Debt Instrument, Fair Value Disclosure decreased by 1.4% to $11.16B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.0%, from $10.73B to $11.16B. Over 4 years (FY 2020 to FY 2024), Debt Instrument, Fair Value Disclosure shows relatively stable performance with a -1.0% CAGR.
other_debt_instrument_fair_value| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.43B | $10.37B | $10.20B | $9.54B | $8.52B | $7.79B | $8.20B | $8.47B | $8.44B | $8.07B | $8.74B | $10.22B | $10.07B | $10.73B | $10.33B | $10.90B | $11.32B | $11.16B |
| QoQ Change | — | -0.6% | -1.7% | -6.4% | -10.7% | -8.5% | +5.3% | +3.2% | -0.3% | -4.4% | +8.3% | +17.0% | -1.5% | +6.6% | -3.8% | +5.5% | +3.8% | -1.4% |
| YoY Change | — | — | — | — | -18.3% | -24.9% | -19.5% | -11.2% | -0.9% | +3.6% | +6.5% | +20.8% | +19.3% | +33.1% | +18.3% | +6.6% | +12.3% | +4.0% |